Axsome Therapeutics
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|
Revenue | $87,166 | $74,999 | $71,530 | $57,794 |
Gross Profit | 77,258 | 66,871 | 64,152 | 51,262 |
EBITDA | -74,033 | -66,855 | -117,710 | -62,120 |
EBIT | -75,886 | -68,686 | -119,450 | -64,205 |
Net Income | -79,345 | -68,357 | -98,651 | -62,199 |
Net Change In Cash | 87,166 | 74,999 | 71,530 | 57,794 |
Free Cash Flow | -30,162 | -53,565 | -30,369 | -53,919 |
Cash | 315,657 | 331,441 | 386,193 | 416,564 |
Basic Shares | 47,573 | 47,393 | 47,329 | 47,117 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $270,600 | $50,037 | $8,819 | $0 |
Gross Profit | 237,701 | 44,839 | -1,155 | -77 |
EBITDA | -176,073 | -170,936 | -123,551 | -99,087 |
EBIT | -182,907 | -176,500 | -124,706 | -99,165 |
Net Income | -239,238 | -197,766 | -134,943 | -105,388 |
Net Change In Cash | 270,600 | 50,037 | 8,819 | 0 |
Cost of Revenue | -97,403 | -36,089 | ||
Free Cash Flow | -145,662 | -117,212 | -108,533 | -78,502 |
Cash | 386,193 | 200,841 | 86,472 | 183,876 |
Basic Shares | 45,425 | 40,655 | 37,618 | 37,206 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-06-30 | -$1.67 |
2024-03-31 | -$1.44 |
2023-12-31 | -$2.08 |
2023-09-30 | -$1.32 |
